

1. U.S. Department of Health, Education, and Welfare. *Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service*. PHS Publication No. 1103. Washington, D.C.: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control; 1964.
2. Office of the Surgeon General, Office on Smoking and Health. *The Health Consequences of Smoking. A Report of the Surgeon General*. Atlanta: Centers for Disease Control and Prevention; 2004.
3. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General*. Atlanta: Centers for Disease Control and Prevention; 2010.
4. U.S. Department of Health and Human Services. *The Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General*. DHHS Publication No. (CDC) 88-8406. Atlanta: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1988.
5. Toll BA, Brandon TH, Gritz ER, et al. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. *Clin Cancer Res* 2013;19:1941–1948.
6. Hanna N, Mulshine J, Wollins DS, et al. Tobacco cessation and control a decade later: American society of clinical oncology policy statement update. *J Clin Oncol* 2013;31:3147–3157.
7. U.S. Department of Health and Human Services. *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
8. Brunzell DH. Preclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotype. *Nicotine Tob Res* 2012;14:1258–1269.
9. Benowitz NL. Nicotine addiction. *N Engl J Med*. 2010;362:2295–2303.
10. Nestler EJ. Is there a common molecular pathway for addiction? *Nat Neurosci* 2005;8:1445–1449.
11. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. *Pharmacol Biochem Behav* 2001;70:439–446.
12. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. *Nicotine Tob Res* 2004;6:899–912.
13. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? *Brain Res Brain Res Rev* 1998;28:309–369.
14. Schultz W. Multiple dopamine functions at different time courses. *Annu Rev Neurosci* 2007;30:259–288.
15. Kalivas PW, McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. *Psychopharmacology* 2003;168:44–56.
16. Dani JA, Balfour DJK. Historical and current perspective on tobacco use and nicotine addiction. *Trends Neurosci* 2011;34:383–439.
17. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. *Eur J Pharmacol* 2000;393:295–314.
18. Centers for Disease Control and Prevention. Current cigarette smoking among adults—United States, 2011. *MMWR Morb Mortal Wkly Rep* 2012;61:889–894.
19. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2001. *MMWR Morb Mortal Wkly Rep* 2003;52:953–956.
20. Smokefree Laws and Policies. American Lung Association Web site. [http://www.lungusa2.org/slati/smokefree\\_laws.php](http://www.lungusa2.org/slati/smokefree_laws.php). Accessed November 25, 2013.
21. Tobacco Policy Project/State Legislated Actions on Tobacco Issues (SLATI). American Lung Association Web site. <http://www.lungusa2.org/slati>. Accessed November 25, 2013.
22. Tobacco Taxes. American Lung Association Web site. [http://www.lungusa2.org/slati/tobacco\\_taxes.php](http://www.lungusa2.org/slati/tobacco_taxes.php). Accessed November 25, 2013.
23. Tobacco Situation and Outlook Report, U.S. Department of Agriculture, U.S. Census 1880-2005.
24. Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. In: *American Society of Clinical Oncology 2013 Educational Book*. 2013; 359–364. ASCO University Web site. <http://meetinglibrary.asco.org/content/200-132>. Accessed November 25, 2013.
25. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med*. 2013;368:351–364.
26. U.S. Food and Drug Administration. Summary of Results: Laboratory Analysis of Electronic Cigarettes Conducted by FDA. U.S. Food and Drug Administration Web site. <http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm173146.htm>. Accessed November 25, 2013.
27. Cummings KM, Dresler CM, Field JK, et al. E-cigarettes and cancer patients. *J Thorac Oncol* 2014;9:438–441.
28. Kuschner WG, Reddy S, Mehrotra N, et al. Electronic cigarettes and third-hand tobacco smoke: two emerging health care challenges for the primary care provider. *Int J Gen Med* 2011;4:115–120.
29. WHO Study Group on Tobacco Product Regulation. WHO Study Group on Tobacco Product Regulation. Report on the scientific basis of tobacco product regulation: third report of a WHO study group. *World Health Organ Tech Rep Ser* 2009;(955):1–41.
30. National Cancer Institute. Cancer Trends Progress Report – 2011/2012 Update. Nation Cancer Institute Web site. <http://progressreport.cancer.gov>. Published August 2012. Accessed November 25, 2013.
31. Bellizzi KM, Rowland JH, Jeffery DD, et al. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. *J Clin Oncol* 2005;23:8884–8893.
32. Coups EJ, Ostroff JS. A population-based estimate of the prevalence of behavioral risk factors among adult cancer survivors and noncancer controls. *Prev Med* 2005;40:702–711.
33. Klosky JL, Hum AM, Zhang N, et al. Smokeless and dual tobacco use among males surviving childhood cancer: a report from the Childhood Cancer Survivor Study. *Cancer Epidemiol Biomarkers Prev* 2013;22:1025–1029.
34. Underwood JM, Townsend JS, Tai E, et al. Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. *J Cancer Surviv* 2012;6:333–344.
35. Walker MS, Vidrine DJ, Gritz ER, et al. Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:2370–2377.
36. Gritz ER. Smoking and smoking cessation in cancer patients. *Br J Addict* 1991;86:549–554.
37. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. *J Natl Cancer Inst* 2001;93:605–618.
38. Ostroff JS, Jacobsen PB, Moadel AB, et al. Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer. *Cancer* 1995;75:569–576.
39. Hickey K, Do KA, Green A. Smoking and prostate cancer. *Epidemiol Rev* 2001;23:115–125.
40. Plaskon LA, Penson DF, Vaughan TL, et al. Cigarette smoking and risk of prostate cancer in middle-aged men. *Cancer Epidemiol Biomarkers Prev* 2003;12:604–609.
41. Watters JL, Park Y, Hollenbeck A, et al. Cigarette smoking and prostate cancer in a prospective US cohort study. *Cancer Epidemiol Biomarkers Prev* 2009;18:2427–2435.
42. Alberg AJ, Singh S, May JW, et al. Epidemiology, prevention, and early detection of breast cancer. *Curr Opin Oncol* 2000;12:515–520.
43. Johnson KC, Miller AB, Collishaw NE, et al. Active smoking and second-hand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). *Tob Control* 2011;20:e2.
44. Breast Cancer Family Registry; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (Australasia); Ontario Cancer Genetics Network (Canada). Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. *Breast Cancer Res Treat* 2008;109:67–75.
45. Warren GW, Marshall JR, Cummings KM, et al. Automated tobacco assessment and cessation support for cancer patients. *Cancer* 2014;120:562–569.
46. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2004. *MMWR Morb Mortal Wkly Rep* 2005;54:1121–1124.
47. Centers for Disease Control and Prevention. Tobacco use among adults—United States, 2005. *MMWR Morb Mortal Wkly Rep* 2006;55:1145–1148.
48. Gritz ER, Nisenbaum R, Elashoff RE, et al. Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer. *Cancer Causes Control* 1991;2:105–112.
49. Chen AM, Vazquez E, Courquin J, et al. Tobacco use among long-term survivors of head and neck cancer treated with radiation therapy. *Psychooncology* 2014;23:190–194.
50. Ostroff J, Garland J, Moadel A, et al. Cigarette smoking patterns in patients after treatment of bladder cancer. *J Cancer Educ* 2000;15:86–90.
51. McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: the case of smoking cessation. *Health Educ Res* 2003;18:156–170.
52. Gritz ER, Schacherer C, Koehly L, et al. Smoking withdrawal and relapse in head and neck cancer patients. *Head Neck* 1999;21:420–427.
53. Warren GW, Marshall JR, Cummings KM. Smoking, cancer treatment, and design of clinical trials. *Proc AACR* 2013;54:594.
54. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. *BMJ* 2010;340:b5569.
55. Peters EN, Torres E, Toll BA, et al. Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. *J Clin Oncol* 2012;30:2869–2875.
56. Land SR. Methodologic barriers to addressing critical questions about tobacco and cancer prognosis. *J Clin Oncol* 2012;30:2030–2032.
57. Gritz ER, Dresler C, Sama L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. *Cancer Epidemiol Biomarkers Prev* 2005;14:2287–2293.

58. Yu GP, Ostroff JS, Zhang ZF, et al. Smoking history and cancer patient survival: a hospital cancer registry study. *Cancer Detect Prev* 1997;21:497–509.
59. Dahlstrom KR, Calzada G, Hanby JD, et al. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. *Cancer* 2012;119:81–89.
60. Molina MA, Cheung MC, Perez EA, et al. African American and poor patients have a dramatically worse prognosis for head and neck cancer: an examination of 20,915 patients. *Cancer* 2008;113:2797–2806.
61. Dragan AE, Huang B, Tucker TC, et al. Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer: impact on overall survival. *Cancer* 2011;117:2590–2598.
62. Bostrom PJ, Alkhatieb S, Trotter G, et al. Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. *BJU Int* 2011;109:70–76.
63. Kroeger N, Klatt T, Birkhäuser FD, et al. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. *Cancer* 2011;118:1795–1802.
64. Marks DI, Ballen K, Logan BR, et al. The effect of smoking on allogeneic transplant outcomes. *Biol Blood Marrow Transplant* 2009;15:1277–1287.
65. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. *J Clin Oncol* 2012;30:3002–3011.
66. Maeda R, Yoshida J, Ishii G, et al. Influence of cigarette smoking on survival and tumor invasiveness in clinical stage IA lung adenocarcinoma. *Ann Thorac Surg* 2012;93:1626–1632.
67. Maeda R, Yoshida J, Ishii G, et al. The prognostic impact of cigarette smoking on patients with non-small cell lung cancer. *J Thorac Oncol* 2011;6:735–742.
68. Janjigian YY, McDonnell K, Kris MG, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. *Cancer* 2010;116:670–675.
69. Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. *Cancer Sci* 2008;99:303–308.
70. Kawai H, Tada A, Kawahara M, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer—a multicenter study. *Lung Cancer* 2005;49:63–70.
71. Warren GW, Kasza K, Reid M, et al. Smoking at diagnosis and survival in cancer patients. *Int J Cancer* 2013;132:401–410.
72. Kvale E, Ekundayo OJ, Zhang Y, et al. History of cancer and mortality in community-dwelling older adults. *Cancer Epidemiol* 2011;35:30–36.
73. Gajdos C, Hawn MT, Campagna EJ, et al. Adverse effects of smoking on postoperative outcomes in cancer patients. *Ann Surg Oncol* 2012;19:1430–1438.
74. Duffy SA, Ronis DL, McLean S, et al. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. *J Clin Oncol* 2009;27:1969–1975.
75. Farshadpour F, Kranenborg H, Calkoen EV, et al. Survival analysis of head and neck squamous cell carcinoma: influence of smoking and drinking. *Head Neck* 2011;33:817–823.
76. Meyer F, Bairati I, Fortin A, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. *Int J Cancer* 2008;122:1679–1683.
77. Shen GP, Xu FH, He F, et al. Pretreatment lifestyle behaviors as survival predictors for patients with nasopharyngeal carcinoma. *PLoS One* 2012;7:e36515.
78. Dal Maso L, Zucchetto A, Talamini R, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. *Int J Cancer* 2008;123:2188–2194.
79. Hellmann SS, Thygesen LC, Tolstrup JS, et al. Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study. *Eur J Cancer Prev* 2010;19:366–673.
80. Holmes MD, Murin S, Chen WY, et al. Smoking and survival after breast cancer diagnosis. *Int J Cancer* 2007;120:2672–2677.
81. Sagiv SK, Gaudet MM, Eng SM, et al. Active and passive cigarette smoke and breast cancer survival. *Ann Epidemiol* 2007;17:385–393.
82. Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: the Seattle Colon Cancer Family Registry. *Cancer* 2011;117:4948–4957.
83. Huang XE, Tajima K, Hamajima N, et al. Effects of dietary, drinking, and smoking habits on the prognosis of gastric cancer. *Nutr Cancer* 2000;38:30–36.
84. Kenfield SA, Stampfer MJ, Chan JM, et al. Smoking and prostate cancer survival and recurrence. *JAMA* 2011;305:2548–2555.
85. Merrick GS, Butler WM, Wallner KE, et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 2006;65:669–677.
86. Pickles T, Liu M, Berthel E, et al. The effect of smoking on outcome following external radiation for localized prostate cancer. *J Urol* 2004;171:1543–1546.
87. Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. *Int J Radiat Oncol Biol Phys* 2011;79:1336–1342.
88. Sweeney C, Farrow DC. Differential survival related to smoking among patients with renal cell carcinoma. *Epidemiology* 2000;11:344–346.
89. Coker AL, DeSimone CP, Eggleston KS, et al. Smoking and survival among Kentucky women diagnosed with invasive cervical cancer: 1995–2005. *Gynecol Oncol* 2009;112:365–369.
90. Modesitt SC, Huang B, Shelton BJ, et al. Endometrial cancer in Kentucky: the impact of age, smoking status, and rural residence. *Gynecol Oncol* 2006;103:300–306.
91. Poullis M, McShane J, Shaw M, et al. Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. *Eur J Cardiothorac Surg* 2012;43:919–924.
92. Kawaguchi T, Tamiya A, Tamura A, et al. Chemotherapy is beneficial for elderly patients with advanced non-small-cell lung cancer: analysis of patients aged 70–74, 75–79, and 80 or older in Japan. *Clin Lung Cancer* 2012;13:442–447.
93. Pirker R, Pereira JR, Szczesna A, et al. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. *Lung Cancer* 2012;77:376–382.
94. Ferketich AK, Niland JC, Mamet R, et al. Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort. *Cancer* 2013;119:847–853.
95. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. *J Thorac Oncol* 2009;4:792–801.
96. Myrdal G, Lamberg K, Lambe M, et al. Regional differences in treatment and outcome in non-small cell lung cancer: a population-based study (Sweden). *Lung Cancer* 2009;63:16–22.
97. Saito-Nakaya K, Nakaya N, Akechi T, et al. Marital status and non-small cell lung cancer survival: the Lung Cancer Database Project in Japan. *Psychooncology*. 2008;17:869–876.
98. Zhou W, Heist RS, Liu G, et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. *Lung Cancer* 2006;53:375–380.
99. Tsao AS, Liu D, Lee JJ, et al. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. *Cancer* 2006;106:2428–2436.
100. Ebbert JO, Williams BA, Sun Z, et al. Duration of smoking abstinence as a predictor for non-small-cell lung cancer survival in women. *Lung Cancer* 2005;47:165–172.
101. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Smoking and lung cancer survival: the role of comorbidity and treatment. *Chest* 2004;125:27–37.
102. Nordquist LT, Simon GR, Cantor A, et al. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. *Chest* 2004;126:347–351.
103. Ehlers SL, Gastineau DA, Patten CA, et al. The impact of smoking on outcomes among patients undergoing hematopoietic SCT for the treatment of acute leukemia. *Bone Marrow Transplant* 2011;46:285–290.
104. Geyer SM, Morton LM, Habermann TM, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. *Cancer* 2010;116:2993–3000.
105. Deleyannis FW, Thomas DB, Vaughan TL, et al. Alcoholism: independent predictor of survival in patients with head and neck cancer. *J Natl Cancer Inst* 1996;88:542–549.
106. Ngô C, Alran S, Plancher C, et al. Outcome in early cervical cancer following pre-operative low dose rate brachytherapy: a ten-year follow up of 257 patients treated at a single institution. *Gynecol Oncol* 2011;123:248–252.
107. Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. *N Engl J Med* 1993;328:159–163.
108. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. *J Clin Oncol* 2012;30:2102–2111.
109. Waggoner SE, Darcy KM, Fuhrman B, et al. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. *Gynecol Oncol* 2006;103:853–858.
110. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. *J Natl Cancer Inst* 2006;98:441–450.
111. Karvonen-Gutierrez CA, Ronis DL, Fowler KE, et al. Quality of life scores predict survival among patients with head and neck cancer. *J Clin Oncol* 2008;26:2754–2760.
112. Sardari Nia P, Weyler J, Colpaert C, et al. Prognostic value of smoking status in operated non-small cell lung cancer. *Lung Cancer* 2005;47:351–359.
113. Chen J, Jiang R, Garces YI, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. *Lung Cancer* 2010;67:221–226.
114. Bittner N, Merrick GS, Galbreath RW, et al. Primary causes of death after permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 2008;72:433–440.
115. Haughey BH, Sinha P. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer. *Laryngoscope* 2012;122:S13–S33.
116. Kawakita D, Hosono S, Ito H, et al. Impact of smoking status on clinical outcome in oral cavity cancer patients. *Oral Oncol* 2012;48:186–191.

117. Chen AM, Chen LM, Vaughan A, et al. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. *Int J Radiat Oncol Biol Phys* 2011;79:414–419.
118. Junor E, Kerr G, Oniscu A, et al. Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. *Br J Cancer* 2012;106:358–365.
119. Manjer J, Andersson I, Berglund G, et al. Survival of women with breast cancer in relation to smoking. *Eur J Surg* 2000;166:852–858.
120. Kountourakis P, Correa AM, Hofstetter WL, et al. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. *Cancer* 2011;117:925–930.
121. Munro AJ, Bentley AH, Ackland C, et al. Smoking compromises cause-specific survival in patients with operable colorectal cancer. *Clin Oncol (R Coll Radiol)* 2006;18:436–440.
122. Gong Z, Agalliu I, Lin DW, et al. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. *Cancer Causes Control* 2008;19:25–31.
123. Kjaerby-Thygesen A, Frederiksen K, Hogdall EV, et al. Smoking and over-weight: negative prognostic factors in stage III epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:798–803.
124. Nagle CM, Bain CJ, Webb PM. Cigarette smoking and survival after ovarian cancer diagnosis. *Cancer Epidemiol Biomarkers Prev* 2006;15:2557–2560.
125. Wright JD, Li J, Gerhard DS, et al. Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. *Gynecol Oncol* 2005;98:84–91.
126. Sardari Nia P, Van Marck E, Weyler J, et al. Prognostic value of a biologic classification of non-small-cell lung cancer into the growth patterns along with other clinical, pathological and immunohistochemical factors. *Eur J Cardiothorac Surg* 2010;38:628–636.
127. Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma—a prospective study. *Radiother Oncol* 2012;103:38–44.
128. Joshi CE, Mondul AM, Meinhold CL, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. *J Natl Cancer Inst* 2011;103:835–838.
129. Mai SK, Welzel G, Haegle V, et al. The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer. *Radiat Oncol* 2007;2:30.
130. Kim AJ, Suh JD, Sercarz JA, et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. *Laryngoscope* 2007;117:1019–1023.
131. Khan AM, Freeman-Wang T, Pisal N, et al. Smoking and multicentric vulva intraepithelial neoplasia. *J Obstet Gynaecol* 2009;29:123–125.
132. Heffler L, Grimm C, Tempfer C, et al. Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial. *Anticancer Res* 2010;30:1257–1261.
133. Matsumoto K, Oki A, Furuta R, et al. Tobacco smoking and regression of low-grade cervical abnormalities. *Cancer Sci* 2010;101:2065–2073.
134. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. *Cancer* 1999;86:2337–2345.
135. Ioffe YJ, Elmore RG, Karlan BY, et al. Effect of cigarette smoking on epithelial ovarian cancer survival. *J Reprod Med* 2010;55:346–350.
136. Schlumbrecht MP, Sun CC, Wong KN, et al. Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. *Cancer* 2011;117:3741–3749.
137. Fortin A, Wang CS, Vigneault E. Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. *Int J Radiat Oncol Biol Phys* 2009;74:1062–1069.
138. Chen CH, Shun CT, Huang KH, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. *BJU Int* 2007;100:281–286.
139. Browman GP, Mohide EA, Willan A, et al. Association between smoking during radiotherapy and prognosis in head and neck cancer: a follow-up study. *Head Neck* 2002;24:1031–1037.
140. Clark JR, McCluskey SA, Hall F, et al. Predictors of morbidity following free flap reconstruction for cancer of the head and neck. *Head Neck* 2007;29:1090–1101.
141. Little SC, Hughley BB, Park SS. Complications with forehead flaps in nasal reconstruction. *Laryngoscope*. 2009;119:1093–1099.
142. Patel RS, McCluskey SA, Goldstein DP, et al. Clinicopathologic and therapeutic risk factors for perioperative complications and prolonged hospital stay in free flap reconstruction of the head and neck. *Head Neck* 2010;32:1345–1353.
143. Baumann DP, Lin HY, Chevray PM. Perforator number predicts fat necrosis in a prospective analysis of breast reconstruction with free TRAM, DIEP, and SIEA flaps. *Plast Reconstr Surg* 2010;125:1335–1341.
144. Goodwin SJ, McCarthy CM, Pusic AL, et al. Complications in smokers after postmastectomy tissue expander/implant breast reconstruction. *Ann Plast Surg* 2005;55:16–19.
145. Bertelsen CA, Andreasen AH, Jorgensen T, et al. Anastomotic leakage after anterior resection for rectal cancer: risk factors. *Colorectal Dis* 2010;12:37–43.
146. Cooke DT, Lin GC, Lau CL, et al. Analysis of cervical esophagogastric anastomotic leaks after transhiatal esophagectomy: risk factors, presentation, and detection. *Ann Thorac Surg* 2009;88:177–184.
147. Richards CH, Platt JJ, Anderson JH, et al. The impact of perioperative risk, tumor pathology and surgical complications on disease recurrence following potentially curative resection of colorectal cancer. *Ann Surg* 2011;254:83–89.
148. Nickelsen TN, Jorgensen T, Kronborg O. Lifestyle and 30-day complications to surgery for colorectal cancer. *Acta Oncol* 2005;44:218–223.
149. Begum FD, Hogdall E, Christensen IJ, et al. Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients. *Gynecol Oncol* 2010;117:446–450.
150. Joo YH, Sun DI, Cho JH, et al. Factors that predict postoperative pulmonary complications after supracricoid partial laryngectomy. *Arch Otolaryngol Head Neck Surg* 2009;135:1154–1157.
151. Mason DP, Subramanian S, Nowicki ER, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. *Ann Thorac Surg* 2009;88:362–370.
152. van der Voet JC, Keus RB, Hart AA, et al. The impact of treatment time and smoking on local control and complications in T1 glottic cancer. *Int J Radiat Oncol Biol Phys* 1998;42:247–255.
153. Wedlake LJ, Thomas K, Lalji A, et al. Predicting late effects of pelvic radiotherapy: is there a better approach? *Int J Radiat Oncol Biol Phys* 2010;78:1163–1170.
154. Hocevar-Boltezar I, Zargi M, Strojan P. Risk factors for voice quality after radiotherapy for early glottic cancer. *Radiother Oncol* 2009;93:524–529.
155. Lilla C, Ambrosone CB, Kropp S, et al. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. *Breast Cancer Res Treat* 2007;106:143–150.
156. Eifel PJ, Jhingran A, Bodurka DC, et al. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. *J Clin Oncol* 2002;20:3651–3657.
157. Wuketich S, Hienz SA, Marosi C. Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors. *Support Care Cancer* 2012;20:175–183.
158. Zevallos JP, Mallen MJ, Lam CY, et al. Complications of radiotherapy in laryngopharyngeal cancer: effects of a prospective smoking cessation program. *Cancer* 2009;115:4636–4644.
159. Gold EB, Flatt SW, Pierce JP, et al. Dietary factors and vasomotor symptoms in breast cancer survivors: the WHEL Study. *Menopause* 2006;13:423–433.
160. Cheung MC, Hamilton K, Sherman R, et al. Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients. *Ann Surg Oncol* 2009;16:3–13.
161. Zingg U, Smithers BM, Gotley DC, et al. Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. *Ann Surg Oncol* 2011;18:1460–1468.
162. Kelly KJ, Greenblatt DY, Wan Y, et al. Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality. *J Gastrointest Surg* 2011;15:250–259.
163. Merkow RP, Bilimoria KY, Cohen ME, et al. Variability in reoperation rates at 182 hospitals: a potential target for quality improvement. *J Am Coll Surg*. 2009;209:557–564.
164. Alsadius D, Hedelin M, Johansson KA, et al. Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer. *Radiother Oncol* 2011;101:495–501.
165. Kuri M, Nakagawa M, Tanaka H, et al. Determination of the duration of preoperative smoking cessation to improve wound healing after head and neck surgery. *Anesthesiology* 2005;102:892–896.
166. Vaporciyan AA, Merriman KW, Ece F, et al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. *Ann Thorac Surg* 2002;73:420–425.
167. Bjarnason GA, Mackenzie RG, Nabid A, et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). *Int J Radiat Oncol Biol Phys* 2009;73:166–172.
168. Park SM, Lim MK, Jung KW, et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. *J Clin Oncol* 2007;25:4835–4843.
169. Leon X, del Prado Venegas M, Orus C, et al. Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case-control study. *Cancer Causes Control* 2009;20:645–652.
170. Kinoshita Y, Tsukuma H, Ajiki W, et al. The risk for second primaries in gastric cancer patients: adjuvant therapy and habitual smoking and drinking. *J Epidemiol* 2000;10:300–304.
171. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. *Cancer Epidemiol Biomarkers Prev* 2001;10:823–829.
172. Scanlon EF, Suh O, Murthy SM, et al. Influence of smoking on the development of lung metastases from breast cancer. *Cancer* 1995;75:2693–2699.
173. Ford MB, Sigurdson AJ, Petrusis ES, et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. *Cancer* 2003;98:1457–1464.
174. Li CI, Daling JR, Porter PL, et al. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. *J Clin Oncol* 2009;27:5312–5318.

175. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. *J Clin Oncol* 2007;25:4370–4378.
176. Boorjian S, Cowan JE, Konety BR, et al. Cancer of the Prostate Strategic Urologic Research Endeavor Investigators. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. *J Urol* 2007;177:883–887.
177. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. *J Natl Cancer Inst* 2002;94:182–192.
178. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010;363:24–35.
179. Peck BW, Dahlstrom KR, Gan SJ, et al. Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. *Head Neck* 2012;35:794–799.
180. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2005;23:5892–5899.
181. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* 2005;366:1527–1537.
182. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693–1703.
183. Paik PK, Johnson ML, D'Angelo SP, et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. *Cancer* 2012;118:5840–5847.
184. Soria JC, Cruz C, Bahleda R, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Presented at: 2013 European Cancer Congress 2013; 2013; Amsterdam.
185. Morales N, Romano M, Cummings KM, et al. Accuracy of self-reported tobacco use in newly diagnosed cancer patients. *Cancer Causes Control* 2013;24:1223–1230.
186. Warren GW, Arnold SM, Valentino JP, et al. Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. *Radiother Oncol* 2012;103:45–48.
187. Marin VP, Pytynia KB, Langstein HN, et al. Serum cotinine concentration and wound complications in head and neck reconstruction. *Plast Reconstr Surg* 2008;121:451–457.
188. American Medical Association. Tobacco use or exposure as a variable in clinical research (Resolution 424, A-06). [www.ama-assn.org/ama1/pub/upload/mm/475/bot479i406.pdf](http://www.ama-assn.org/ama1/pub/upload/mm/475/bot479i406.pdf).
189. Sama L, Bialous SA. Nursing and tobacco cessation: setting a research agenda. Reports from a national conference. In: *Nursing Research*. Philadelphia: Lippincott Williams & Wilkins; 2006: 4S.
190. Sama L, Bialous SA, Chan S, et al. International symposia: global perspectives on nursing involvement in tobacco control. Presented in: *Oncology Nursing Society, 28th Annual Congress Syllabus*, May 1–4, 2003, Denver, Colorado. Denver: Oncology Nursing Society; 2003: 112.
191. Viswanath K, Herbst RS, Land SR, et al. Tobacco and cancer: an American Association for Cancer research policy statement. *Cancer Res* 2010;70(17):3419–3430.
192. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: tobacco control—Reducing cancer incidence and saving lives. 2003. *J Clin Oncol* 2003;21:2777–2786.
193. Gritz ER, Fingeret MC, Vidrine DJ, et al. Successes and failures of the teachable moment: smoking cessation in cancer patients. *Cancer* 2006;106:17–27.
194. Gritz ER, Dresler C, Sama L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. *Cancer Epidemiol Biomarkers Prev* 2005;14:2287–2293.
195. Chappel A, Ziebland S, McPherson A. Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. *BMJ* 2004;328:1470.
196. LoConte NK, Else-Quest NM, Eickhoff J, et al. Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancer. *Clin Lung Cancer* 2008;9:171–178.
197. Wassenaar TR, Eickhoff JC, Jarzemycki DR, et al. Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer. *J Thorac Oncol* 2007;2:722–728.
198. Fiore MC, Bailey WC, Cohen SJ, et al. *Quick Reference Guide for Clinicians. Treating Tobacco Use and Dependence*. Rockville, MD: U.S. Department of Health and Human Services, Public Health Services; 2000. [http://health.state.tn.us/Downloads/TQL\\_Quick%20Reference.pdf](http://health.state.tn.us/Downloads/TQL_Quick%20Reference.pdf). Accessed November 25, 2013.
199. Fiore MC, Jaén CR, Baker TB, et al. *Treating Tobacco Use and Dependence: 2008 Update*. Rockville, MD: U.S. Department of Health and Human Services; 2008. <http://www.ncbi.nlm.nih.gov/books/NBK63952/>. Accessed November 25, 2013.
200. Fiore MC, Jorenby DE, Schenck AE, et al. Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. *Mayo Clin Proc* 1995;70:209–213.
201. Blumenthal D, Tavenner M. The “meaningful use” regulation for electronic health records. *N Engl J Med* 2010;363:501–504.
202. Couple approaches to smoking cessation. In: Schmalzing KB, Sher TG, eds. *The Psychology of Couples and Illness: Theory, Research, & Practice*. Washington, D.C.: American Psychological Association; 2000: 311–336.
203. Homish GG, Leonard KE. Spousal influence on smoking behaviors in a US community sample of newly married couples. *Soc Sci Med* 2005;61:2557–2567.
204. Hensing N, Greaves L, O'Leary R, et al. Partner support for smoking cessation during pregnancy: a systematic review. *Nicotine Tob Res* 2012;14:767–776.
205. Tod AM, Joanne R. Overcoming delay in the diagnosis of lung cancer: a qualitative study. *Nurs Stan* 2010;24:35–43.
206. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. *J Behav Med* 1989;12:159–182.
207. Baker TB, Piper ME, Bolt DM, et al. Time to first cigarette in the morning smoking as an index of ability to quit smoking: implications for nicotine dependence. *Nicotine Tob Res* 2007;9:S555–S570.
208. Ferguson JA, Patten CA, Schroeder DR, et al. Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence. *Addict Behav* 2003;28:1203–1218.
209. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. *J Consult Clin Psychol* 1983;51:390–395.
210. Prokhorov AV, Hudmon KS, Gritz ER. Promoting smoking cessation among cancer patients: a behavioral model. *Oncology (Williston Park)* 1997;11:1807–1813.
211. Toll BA, Rojewski AM, Duncan L, et al. “Quitting smoking will benefit your health”: the evolution of clinician messaging to encourage tobacco cessation. *Clin Cancer Res* 2014;20:301–309.
212. Miller WR, Rose GS. Toward a theory of motivational interviewing. *Am Psychol* 2009;64:527–537.
213. Gritz ER, Fingeret MC, Vidrine DJ. Tobacco control in the oncology setting. In: Brawley OW, Khuri FR, Rock CL, eds. *ASCO Cancer Prevention Curriculum*. Alexandria, VA: American Society of Clinical Oncology; 2007.
214. Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. *J Consult Clin Psychol* 1993;61:743–750.
215. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev* 2004;(3):CD000146.
216. Piper M, Smith S, Schlam T, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry* 2009;66:1253–1262.
217. Smith S, McCarthy D, Japuntich S, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. *Arch Intern Med* 2009;169:2148–2155.
218. Warren GW, Singh AK. Nicotine and lung cancer. *J Carcinog* 2013;12:1–8.
219. Myles PS, Iacono GA, Hunt JO, et al. Risk of respiratory complications and wound infection in patients undergoing ambulatory surgery: smokers versus nonsmokers. *Anesthesiology* 2002;97:842–847.
220. Sørensen L, Hørby J, Friis E, et al. Smoking as a risk factor for wound healing and infection in breast cancer surgery. *Eur J Surg Oncol* 2002;28:815–820.
221. Jørgensen ED, Zhao H, Traganos F, et al. DNA damage response induced by exposure of human lung adenocarcinoma cells to smoke from tobacco- and nicotine-free cigarettes. *Cell Cycle* 2010;9:2170–2176.
222. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. *Nicotine Tob Res* 2009;11:1076–1082.
223. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. *Nicotine Tob Res* 2005;7:491–499.
224. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. *J Clin Psychiatry* 1995;56:395–401.
225. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phenylcyclidine, and ibogaine. *J Pharmacol Exp Ther* 1999;288:88–92.
226. Cryan JF, Buijnzeel AW, Skjei KL, et al. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. *Psychopharmacology* 2003;168:347–358.
227. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2003;(2):CD000031.
228. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. *J Med Chem* 2005;48:3474–3477.
229. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:56–63.
230. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev* 2012;4:CD006103.
231. Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. *Curr Med Res Opin* 2008;24:51–61.
232. Linden K, Jormanainen V, Linna M, et al. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. *Curr Med Res Opin* 2010;26:549–560.
233. Zimovetz EA, Wilson K, Samuel M, et al. A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities. *J Eval Clin Pract* 2011;17:288–297.
234. Gibbons RD, Mann JJ, Varenicline, smoking cessation, and neuropsychiatric adverse events. *Am J of Psychiatry* 2013;170:1460–1467.

235. Thomas KH, Martin RM, Davies NM, et al. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. *BMJ* 2013;347:f5704.
236. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. *Ann Intern Med* 2013;159:390–400.
237. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. *Cochrane Database Syst Rev* 2004;(3):CD000058.
238. Gritz ER, Carr CR, Rapkin D, et al. Predictors of long-term smoking cessation in head and neck cancer patients. *Cancer Epidemiol Biomarkers Prev* 1993;2:261–270.
239. Schnoll RA, Rothman RL, Wielt DB, et al. A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. *Ann Behav Med* 2005;30:1–11.
240. Griebel B, Wewers ME, Baker CA. The effectiveness of a nurse-managed minimal smoking-cessation intervention among hospitalized patients with cancer. *Oncol Nurs Forum* 1998;25:897–902.
241. Wewers ME, Bowen JM, Stanislaw AE, et al. A nurse-delivered smoking cessation intervention among hospitalized postoperative patients—influence of a smoking-related diagnosis: a pilot study. *Heart Lung* 1994;23:151–156.
242. Wewers ME, Jenkins L, Mignery T. A nurse-managed smoking cessation intervention during diagnostic testing for lung cancer. *Oncol Nurs Forum* 1997;24:1419–1422.
243. Stanislaw AE, Wewers ME. A smoking cessation intervention with hospitalized surgical cancer patients: a pilot study. *Cancer Nurs* 1994;17:81–86.
244. Schnoll RA, Zhang B, Rue M, et al. Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol* 2003;21:355–365.
245. Sanderson Cox L, Patten CA, Ebbert JO, et al. Tobacco use outcomes among patients with lung cancer treated for nicotine dependence. *J Clin Oncol* 2002;20:3461–3469.
246. Garces YI, Schroeder DR, Nirelli LM, et al. Tobacco use outcomes among patients with head and neck carcinoma treated for nicotine dependence: a matched-pair analysis. *Cancer* 2004;101:116–124.
247. Duffy SA, Ronis DL, Valenstein M, et al. A tailored smoking, alcohol, and depression intervention for head and neck cancer patients. *Cancer Epidemiol Biomarkers Prev* 2006;15:2203–2208.
248. Schnoll RA, Martinez E, Tatum KL, et al. A bupropion smoking cessation clinical trial for cancer patients. *Cancer Causes Control* 2010;21:811–820.
249. Martinez E, Tatum KL, Weber DM, et al. Issues related to implementing a smoking cessation clinical trial for cancer patients. *Cancer Causes Control* 2009;20:97–104.
250. Park ER, Japuntich S, Temel J, et al. A smoking cessation intervention for thoracic surgery and oncology clinics: a pilot trial. *J Thorac Oncol* 2011;6:1059–1065.
251. Ostroff JS, Burkhalter JE, Cinciripini PM, et al. Randomized trial of a presurgical scheduled reduced smoking intervention for patients newly diagnosed with cancer. *Health Psychol* 2013 [Epub ahead of print].
252. Emmons KM, Puleo E, Park E, et al. Peer-delivered smoking counseling for childhood cancer survivors increases rate of cessation: the partnership for health study. *J Clin Oncol* 2005;23:6516–6523.
253. Wakefield M, Olver I, Whitford H, et al. Motivational interviewing as a smoking cessation intervention for patients with cancer: randomized controlled trial. *Nurs Res* 2004;53:396–406.
254. Goldstein AO, Ripley-Moffitt CE, Pathman DE, et al. Tobacco use treatment at the U.S. National Cancer Institute's designated Cancer Centers. *Nicotine Tob Res* 2013;15:52–58.
255. Warren GW, Marshall JR, Cummings KM, et al. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. *J Thorac Oncol* 2013;8:543–548.
256. Warren GW, Marshall JR, Cummings KM, et al. Addressing tobacco use in cancer patients: a survey of American Society of Clinical Oncology (ASCO) members. *J Oncol Pract* 2013;9:258–262.
257. Gritz ER, Sarna L, Dresler C, et al. Building a united front: aligning the agendas for tobacco control, lung cancer research, and policy. *Cancer Epidemiol Biomarkers Prev* 2007;16:859–863.
258. Vidrine JI, Shete S, Cao Y, et al. Ask-Advise-Connect: a new approach to smoking treatment delivery in health care settings. *JAMA Intern Med* 2013;173:458–464.
259. Bernstein SL, Jearld S, Prasad D, et al. Rapid implementation of a smokers' quitline fax referral service in an urban area. *J Health Care Poor Underserved* 2009;20:55–63.
260. Sarna L, Bialous SA, Ong MK, et al. Increasing nursing referral to telephone quitlines for smoking cessation using a web-based program. *Nurs Res* 2012;61:433–440.
261. Stancic N, Mullen PD, Prokhorov AV, et al. Continuing medical education: what delivery format do physicians prefer? *J Contin Educ Health Prof* 2003;23:162–167.
262. Society for Research on Nicotine and Tobacco Committee on Biochemical Verification. Biochemical verification of tobacco use and cessation. *Nicotine Tob Res* 2002;4:149–159.
263. American Society of Clinical Oncology. Tobacco Cessation Guide: for Oncology Providers. ASCO Web site. [http://www.asco.org/sites/default/files/tobacco\\_cessation\\_guide.pdf](http://www.asco.org/sites/default/files/tobacco_cessation_guide.pdf). Accessed November 25, 2013.